Prostate cancer prevention: What do we know now, and when will we know more?

Ian M. Thompson, Joseph Basler, Deborah Hensley, Dendra Von Merveldt, Carol A. Jenkins, Betsy Higgins, Robin Leach, Dean Troyer, Bradley H Pollock

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.

Original languageEnglish (US)
Pages (from-to)215-220
Number of pages6
JournalClinical Prostate Cancer
Volume1
Issue number4
StatePublished - Mar 2003
Externally publishedYes

Fingerprint

Selenium
Vitamin E
Prostatic Neoplasms
Finasteride
Prostate
Appointments and Schedules
Biomarkers
Clinical Trials
Biopsy
Neoplasms

Keywords

  • Biomarker
  • Early detection
  • Hormonal agents
  • Selenium
  • Vitamin E

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Thompson, I. M., Basler, J., Hensley, D., Von Merveldt, D., Jenkins, C. A., Higgins, B., ... Pollock, B. H. (2003). Prostate cancer prevention: What do we know now, and when will we know more? Clinical Prostate Cancer, 1(4), 215-220.

Prostate cancer prevention : What do we know now, and when will we know more? / Thompson, Ian M.; Basler, Joseph; Hensley, Deborah; Von Merveldt, Dendra; Jenkins, Carol A.; Higgins, Betsy; Leach, Robin; Troyer, Dean; Pollock, Bradley H.

In: Clinical Prostate Cancer, Vol. 1, No. 4, 03.2003, p. 215-220.

Research output: Contribution to journalReview article

Thompson, IM, Basler, J, Hensley, D, Von Merveldt, D, Jenkins, CA, Higgins, B, Leach, R, Troyer, D & Pollock, BH 2003, 'Prostate cancer prevention: What do we know now, and when will we know more?', Clinical Prostate Cancer, vol. 1, no. 4, pp. 215-220.
Thompson IM, Basler J, Hensley D, Von Merveldt D, Jenkins CA, Higgins B et al. Prostate cancer prevention: What do we know now, and when will we know more? Clinical Prostate Cancer. 2003 Mar;1(4):215-220.
Thompson, Ian M. ; Basler, Joseph ; Hensley, Deborah ; Von Merveldt, Dendra ; Jenkins, Carol A. ; Higgins, Betsy ; Leach, Robin ; Troyer, Dean ; Pollock, Bradley H. / Prostate cancer prevention : What do we know now, and when will we know more?. In: Clinical Prostate Cancer. 2003 ; Vol. 1, No. 4. pp. 215-220.
@article{d9fa050b158145118cc9db08c5b40150,
title = "Prostate cancer prevention: What do we know now, and when will we know more?",
abstract = "Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.",
keywords = "Biomarker, Early detection, Hormonal agents, Selenium, Vitamin E",
author = "Thompson, {Ian M.} and Joseph Basler and Deborah Hensley and {Von Merveldt}, Dendra and Jenkins, {Carol A.} and Betsy Higgins and Robin Leach and Dean Troyer and Pollock, {Bradley H}",
year = "2003",
month = "3",
language = "English (US)",
volume = "1",
pages = "215--220",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Prostate cancer prevention

T2 - What do we know now, and when will we know more?

AU - Thompson, Ian M.

AU - Basler, Joseph

AU - Hensley, Deborah

AU - Von Merveldt, Dendra

AU - Jenkins, Carol A.

AU - Higgins, Betsy

AU - Leach, Robin

AU - Troyer, Dean

AU - Pollock, Bradley H

PY - 2003/3

Y1 - 2003/3

N2 - Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.

AB - Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.

KW - Biomarker

KW - Early detection

KW - Hormonal agents

KW - Selenium

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=0041970199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041970199&partnerID=8YFLogxK

M3 - Review article

C2 - 15040879

AN - SCOPUS:0041970199

VL - 1

SP - 215

EP - 220

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 4

ER -